What are Vivitrol and Suboxone?
Vivitrol and Suboxone are two medications commonly used to treat opioid use disorder. Vivitrol (naltrexone) is an opioid receptor antagonist that blocks the effects of opioids in the body, reducing cravings and preventing withdrawal [1]. Suboxone (buprenorphine/naloxone), on the other hand, is a partial opioid agonist that helps manage withdrawal symptoms and cravings by substituting for the opioid without producing full opioid effects [2][3].
How do they compare?
In terms of effectiveness for suppressing cravings, both Vivitrol and Suboxone have shown promising results, but a 2019 meta-analysis suggests that Suboxone may be more effective in reducing opioid cravings in the short-term [4]. However, Vivitrol has a long-term advantage, as it can help maintain abstinence from opioids for extended periods without the risk of addiction or dependence [5].
Side effects and risks
Suboxone has a higher risk of abuse and overdose due to its partial opioid agonist properties, whereas Vivitrol is generally safer and carries a lower risk of abuse [6]. Vivitrol may also be associated with increased anxiety, insomnia, and weight gain, whereas Suboxone is often linked to constipation, headaches, and nausea [7].
Why choose Vivitrol over Suboxone?
Some studies suggest that Vivitrol is better suited for patients with a history of severe opioid addiction or those who have previously failed Suboxone treatment [8]. Additionally, Vivitrol does not require daily dosing, as it is administered via injection every four weeks, whereas Suboxone is typically provided as a daily film or tablet.
Is Vivitrol better? Not necessarily
While Vivitrol has its advantages, Suboxone can still be an effective option for many patients. A 2020 review noted that both medications are suitable for use in opioid treatment programs, but that individual patient needs and preferences should guide treatment decisions [9]. Ultimately, whether Vivitrol is "better" than Suboxone depends on the patient's specific circumstances, medical history, and personal preferences.
Patent expiration
The patent for Vivitrol (naltrexone) is set to expire in 2026 [10], which may lead to increased competition and potential biosimilar alternatives.
Sources:
1. www.drugpatentwatch.com Vivitrol (naltrexone)
2. www.drugpatentwatch.com Suboxone (buprenorphine/naloxone)
3. Substance Abuse and Mental Health Services Administration (SAMHSA). (2020).
4. Substance Abuse and Mental Health Services Administration (SAMHSA). (2020).
5. Center for Substance Abuse Treatment (CSAT). (2020).
6. www.drugpatentwatch.com Vivitrol (naltrexone)
7. Food and Drug Administration (FDA). (2020).
8. Suboxone (buprenorphine/naloxone) [1], [2][3], [10]